Articles Archive:

Systems & Services - Why is cancer killing more men than women?


A rising focus on men's health issues, more sophisticated registry data and new techniques for investigating the biology of cancers are fuelling interest in unravelling what lies behind gender differences in cancer incidence and mortality. Getting answers could boost prevention and early detection and could even lead to better targeted therapies.

Drug Watch - Oncology's successes must not fail the heart


Targeted therapies seek to close down signalling pathways that allow tumours to prosper. But these pathways may also be vital to other clinical functions. With rising concern about collateral cardiac damage from cancer treatment comes a call for a new partnership between oncology and cardiology, to avoid problems and to treat them quickly and expertly if they do arise.

Cutting Edge - Who's who in the world of personalised cancer treatments?


The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal.

e-Grand Round - Optimising dose-dense regimens for early breast cancer


Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added.

Cover Story - Siddhartha Mukherjee: explaining cancer


With our new-found understanding of cancer biology comes the opportunity to explain a disease that for centuries has confounded doctors and engendered stigma and superstition. Siddhartha Mukherjee took that opportunity and turned it into a best seller.

Cover Story - Andreas Engert: Learning from Hodgkin's


Hodgkin's patients survive for longer – but with more serious and lasting damage – than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can provide valuable lessons for other cancers.

e-Grand Round - Skin toxicities caused by targeted therapies


Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure symptoms are identified and managed.

e-Grand Round - Personalised cancer care: where do we stand today?


Since the concept of personalised cancer therapies first emerged, the picture has become so much more complex and challenging.

Cover Story - Jim Watson: DNA revealed the causes, it may never reveal a cure


Nobel laureate Jim Watson is calling on the cancer community to take a long hard look at what has been achieved by blocking the molecular signals that drive individual cancers

Cover Story - Enriqueta Felip: breaking boundaries in lung cancer


Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta FelipÂ’s career. Her focus today is on increasing collaboration across Europe, which she sees as key if patients are to benefit quickly from the new opportunities offered by personalised therapies.

Cover Story - Marcel Verheij: Revolutionising radiotherapy


Could intelligent combinations of drugs and radiation take precision radiotherapy to new levels? Marcel Verheij believes so, but may struggle to prove it without a fairer share of funding

Patient Voice - Side effects of targeted treatments: clinicians' perceptions, patients' realities


The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life.

Cutting Edge - Targeting the supply lines: metabolic approaches to killing cancer cells


Recent years have seen a revival of interest in the unique metabolism of cancer cells. This time the focus is on the potential it offers as a target, rather than any possible causal role – but that link with obesity still needs explaining.

Cutting Edge - What can we learn from liquid biopsies?


Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.